Age-related Curves of AMH Using the Gen II, the PicoAMH, and the Elecsys Assays in Women With Polycystic Ovary Syndrome

Overview

Journal J Clin Endocrinol Metab

Publisher Oxford University Press

Specialty Endocrinology

Date 2024 Mar 15

PMID 38486510

Authors

Federica Barbagallo

Kim van der Ham

Sten P Willemsen

Yvonne V Louwers

Joop S Laven

Affiliations

Soon will be listed here.

Abstract

Context: Several challenges still exist to adopt the anti-müllerian hormone (AMH) as a marker of polycystic ovary morphology, as included in the recently updated international guideline. Although different evaluations of age- and assay-specific reference ranges have been published in the past few years, these studies have mainly been conducted in normo-ovulatory or infertile women.

Objective: To develop an age-specific percentile distribution of AMH in patients with polycystic ovary syndrome (PCOS) measured by 3 different assays.

Design: Retrospective cross-sectional study.

Patients: A total of 2725 women aged 20 to 40 years with PCOS diagnosis were included.

Interventions: Serum AMH measurement by the Gen II (Beckman Coulter), the picoAMH (Ansh Labs), and the Elecsys (Roche) assays.

Main Outcome Measures: Age-specific percentile curves for all the assays and correlations between AMH, clinical, hormonal, and ultrasound characteristics.

Results: Age-related nomograms for the 5th, 10th, 25th, 50th, 75th, 90th, and 95th percentiles of AMH were calculated using the Lambda-Mu-Sigma method for all the assays. AMH levels were significantly different between PCOS phenotypes. AMH levels were positively correlated to LH, LH/FSH ratio, testosterone, androstenedione, free androgen index, mean follicular number, and mean ovarian volume.

Conclusion: To our knowledge, this is the first study reporting age-specific percentile nomograms of serum AMH levels measured by the Gen II, the picoAMH, and the Elecsys assays in a large population of women with PCOS. These findings may help to interpret AMH levels in patients with PCOS and facilitate the use of AMH as a diagnostic tool across age ranges.

Citing Articles

SmartScanPCOS: A feature-driven approach to cutting-edge prediction of Polycystic Ovary Syndrome using Machine Learning and Explainable Artificial Intelligence.

G U, Maheswari P U Heliyon. 2024; 10(20):e39205.

PMID: 39492914 PMC: 11530826. DOI: 10.1016/j.heliyon.2024.e39205.

Anti-Müllerian hormone a surrogate of follicular fluid oxidative stress in polycystic ovary syndrome?.

Vale-Fernandes E, Moreira M, Rodrigues B, Pereira S, Leal C, Barreiro M Front Cell Dev Biol. 2024; 12:1408879.

PMID: 39011395 PMC: 11246868. DOI: 10.3389/fcell.2024.1408879.

Barbagallo F, van der Ham K, Willemsen S, Louwers Y, Laven J J Clin Endocrinol Metab. 2024; 109(10):2561-2570.

PMID: 38486510 PMC: 11403310. DOI: 10.1210/clinem/dgae153.

References

Moolhuijsen L, Visser J . Anti-Müllerian Hormone and Ovarian Reserve: Update on Assessing Ovarian Function. J Clin Endocrinol Metab. 2020; 105(11). PMC: 7486884. DOI: 10.1210/clinem/dgaa513. View

Cole T, Green P . Smoothing reference centile curves: the LMS method and penalized likelihood. Stat Med. 1992; 11(10):1305-19. DOI: 10.1002/sim.4780111005. View

Li H, Nelson S . Clinical Application of AMH Measurement in Assisted Reproduction. Front Endocrinol (Lausanne). 2020; 11:606744. PMC: 7757755. DOI: 10.3389/fendo.2020.606744. View

Bell R, Islam R, Skiba M, Herbert D, Martinez Garcia A, Davis S . Substituting serum anti-Müllerian hormone for polycystic ovary morphology increases the number of women diagnosed with polycystic ovary syndrome: a community-based cross-sectional study. Hum Reprod. 2021; 37(1):109-118. DOI: 10.1093/humrep/deab232. View

Bernardi L, Weiss M, Waldo A, Harmon Q, Carnethon M, Baird D . Duration, recency, and type of hormonal contraceptive use and antimüllerian hormone levels. Fertil Steril. 2021; 116(1):208-217. PMC: 8217153. DOI: 10.1016/j.fertnstert.2021.02.007. View

Piltonen T, Morin-Papunen L, Koivunen R, Perheentupa A, Ruokonen A, Tapanainen J . Serum anti-Müllerian hormone levels remain high until late reproductive age and decrease during metformin therapy in women with polycystic ovary syndrome. Hum Reprod. 2005; 20(7):1820-6. DOI: 10.1093/humrep/deh850. View

Zhang Y, Xu Y, Xue Q, Shang J, Yang X, Shan X . Discordance between antral follicle counts and anti-Müllerian hormone levels in women undergoing in vitro fertilization. Reprod Biol Endocrinol. 2019; 17(1):51. PMC: 6610959. DOI: 10.1186/s12958-019-0497-4. View

Pigny P, Jonard S, Robert Y, Dewailly D . Serum anti-Mullerian hormone as a surrogate for antral follicle count for definition of the polycystic ovary syndrome. J Clin Endocrinol Metab. 2005; 91(3):941-5. DOI: 10.1210/jc.2005-2076. View

Teede H, Misso M, Costello M, Dokras A, Laven J, Moran L . Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome. Hum Reprod. 2018; 33(9):1602-1618. PMC: 6112576. DOI: 10.1093/humrep/dey256. View

10.

Pellatt L, Rice S, D Mason H . Anti-Müllerian hormone and polycystic ovary syndrome: a mountain too high?. Reproduction. 2010; 139(5):825-33. DOI: 10.1530/REP-09-0415. View

11.

van Helden J, Weiskirchen R . Age-independent anti-Müllerian hormone (AMH) standard deviation scores to estimate ovarian function. Eur J Obstet Gynecol Reprod Biol. 2017; 213:64-70. DOI: 10.1016/j.ejogrb.2017.04.029. View

12.

Seifer D, MacLaughlin D . Mullerian Inhibiting Substance is an ovarian growth factor of emerging clinical significance. Fertil Steril. 2007; 88(3):539-46. DOI: 10.1016/j.fertnstert.2007.02.014. View

13.

Romualdi D, Di Florio C, Tagliaferri V, De Cicco S, Gagliano D, Immediata V . The Role of Anti-Müllerian Hormone in the Characterization of the Different Polycystic Ovary Syndrome Phenotypes. Reprod Sci. 2016; 23(5):655-61. DOI: 10.1177/1933719115611751. View

14.

Teede H, Tay C, Laven J, Dokras A, Moran L, Piltonen T . Recommendations From the 2023 International Evidence-based Guideline for the Assessment and Management of Polycystic Ovary Syndrome. J Clin Endocrinol Metab. 2023; 108(10):2447-2469. PMC: 10505534. DOI: 10.1210/clinem/dgad463. View

15.

Pigny P, Merlen E, Robert Y, Cortet-Rudelli C, Decanter C, Jonard S . Elevated serum level of anti-mullerian hormone in patients with polycystic ovary syndrome: relationship to the ovarian follicle excess and to the follicular arrest. J Clin Endocrinol Metab. 2003; 88(12):5957-62. DOI: 10.1210/jc.2003-030727. View

16.

Dewailly D, Lujan M, Carmina E, Cedars M, Laven J, Norman R . Definition and significance of polycystic ovarian morphology: a task force report from the Androgen Excess and Polycystic Ovary Syndrome Society. Hum Reprod Update. 2013; 20(3):334-52. DOI: 10.1093/humupd/dmt061. View

17.

Moolhuijsen L, Louwers Y, Laven J, Visser J . Comparison of 3 Different AMH Assays With AMH Levels and Follicle Count in Women With Polycystic Ovary Syndrome. J Clin Endocrinol Metab. 2022; 107(9):e3714-e3722. PMC: 9387710. DOI: 10.1210/clinem/dgac370. View

18.

Anand S, Kumar A, Prasad A, Trivedi K . Updated meta-analysis on the diagnostic accuracy of serum anti-Mullerian hormone in poly cystic ovary syndrome involving 13 509 subjects. J Obstet Gynaecol Res. 2022; 48(8):2162-2174. DOI: 10.1111/jog.15233. View

19.

Cook C, Siow Y, Brenner A, Fallat M . Relationship between serum müllerian-inhibiting substance and other reproductive hormones in untreated women with polycystic ovary syndrome and normal women. Fertil Steril. 2002; 77(1):141-6. DOI: 10.1016/s0015-0282(01)02944-2. View

20.

Shebl O, Ebner T, Sir A, Schreier-Lechner E, Mayer R, Tews G . Age-related distribution of basal serum AMH level in women of reproductive age and a presumably healthy cohort. Fertil Steril. 2010; 95(2):832-4. DOI: 10.1016/j.fertnstert.2010.09.012. View